Fineline Cube

Follow:
14435 Articles
CSPC Pharmaceutical's mRNA Vaccine SYS6017 Gains NMPA Approval for Herpes Zoster Study
CompanyDrug

CSPC Pharmaceutical’s mRNA Vaccine SYS6017 Gains NMPA Approval for Herpes Zoster Study

Nuance Pharma's Ohtuvayre Receives Regulatory Approval in Macau for COPD Treatment
CompanyDrug

Nuance Pharma’s Ohtuvayre Receives Regulatory Approval in Macau for COPD Treatment

Regend Therapeutics' Pulmovinci Receives FDA Orphan Drug Designation for IPF
Company

Regend Therapeutics’ Pulmovinci Receives FDA Orphan Drug Designation for IPF

Sichuan Kelun-Biotech's Datailai Gains NMPA Approval for Colorectal Cancer Treatment
CompanyDrug

Sichuan Kelun-Biotech’s Datailai Gains NMPA Approval for Colorectal Cancer Treatment

CanSino Biologics' DTcP Vaccine for Infants Gains Priority Review in China
CompanyDrug

CanSino Biologics’ DTcP Vaccine for Infants Gains Priority Review in China

Keymed Biosciences' Kangyueda Gains NMPA Approval for Seasonal Allergic Rhinitis
CompanyDrug

Keymed Biosciences’ Kangyueda Gains NMPA Approval for Seasonal Allergic Rhinitis

Novo Nordisk's Mim8 Shows Promise in Hemophilia A Trial with 98% Caregiver Preference
CompanyDrug

Novo Nordisk’s Mim8 Shows Promise in Hemophilia A Trial with 98% Caregiver Preference

RemeGen's Executive Director He Ruyi Resigns for Career Development
Company

RemeGen’s Executive Director He Ruyi Resigns for Career Development

Biokin Pharmaceutical's BL-M07D1 Gains NMPA Approval for Phase III Study
CompanyDrug

Biokin Pharmaceutical’s BL-M07D1 Gains NMPA Approval for Phase III Study

AbbVie's Emblaveo Wins FDA Approval for Complicated Intra-Abdominal Infections
CompanyDrug

AbbVie’s Emblaveo Wins FDA Approval for Complicated Intra-Abdominal Infections

Zhongsheng Pharma Gains FDA Approval for Phase II Study of RAY1225
CompanyDrug

Zhongsheng Pharma Gains FDA Approval for Phase II Study of RAY1225

Siemens Healthineers Posts Strong Q1 Results with 5.7% Revenue Growth
CompanyMedical Device

Siemens Healthineers Posts Strong Q1 Results with 5.7% Revenue Growth